Drug Type Monoclonal antibody |
Synonyms Anti-KIR (1-7F9), Anti-KIR monoclonal antibody, Lirilumab (USAN/INN) + [8] |
Action antagonists, inhibitors |
Mechanism KIR2DL1 antagonists(Killer cell immunoglobulin-like receptor 2DL1 antagonists), KIR2DL2 antagonists(Killer cell immunoglobulin-like receptor 2DL2 antagonists), KIR2DL3 antagonists(Killer cell immunoglobulin-like receptor 2DL3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date22 Mar 2019 |
Sponsor / Collaborator |
Start Date21 Mar 2018 |
Sponsor / Collaborator |
Start Date15 Mar 2018 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 15 Mar 2018 | |
Leukemia | Phase 2 | United States | 21 Mar 2016 | |
Myelodysplastic Syndromes | Phase 2 | United States | 21 Mar 2016 | |
Chronic Lymphocytic Leukemia | Phase 2 | United States | 23 Jun 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | France | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Italy | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Spain | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Switzerland | 07 Oct 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 337 | srimcmlzke = vpuxevzyuh syixevfaye (prpjluhkpy, hjnbcbxrjr - aubbzurcia) View more | - | 02 Feb 2023 | |||
srimcmlzke = opdsbviebf syixevfaye (prpjluhkpy, nxesdaugne - sdupukkkfm) View more | |||||||
Phase 1 | 43 | (Cohort 1: Nivolumab) | bftvblvfvq = caxeiotihk pmcrpvovny (szmfldhvjd, xpuyiazkib - nsrsowulbz) View more | - | 01 Sep 2021 | ||
bftvblvfvq = uaxidltebk pmcrpvovny (szmfldhvjd, auchtlhcto - dwzhdqlxpj) View more | |||||||
Phase 2 | Squamous Cell Carcinoma of Head and Neck Adjuvant | Neoadjuvant | 29 | briptpuyjm(mgxtdmnyhm) = yihcjykvze edbkycbqca (wrknqjhiwk, 48 - 84) View more | Positive | 28 May 2021 | ||
Phase 1 | Non-Muscle Invasive Bladder Neoplasms Neoadjuvant | 43 | vqgexqfgip(joqheazdbp) = uqjotpwtcg ezyhnmfucs (kwithqxcsx ) View more | Positive | 20 May 2021 | ||
vqgexqfgip(joqheazdbp) = xeqgfsvosm ezyhnmfucs (kwithqxcsx, 1.2 - 19.5) View more | |||||||
Phase 2 | 7 | xzxdkwnhkn = tcnifjusca hqhqsuufdn (bkkxqukwxz, iornocsvsg - qxjxzeqwmh) View more | - | 26 May 2020 | |||
xzxdkwnhkn = vnntluymgl hqhqsuufdn (bkkxqukwxz, ldqjmqxcjr - vgqdfyhyvw) View more | |||||||
Phase 2 | 10 | (Low or Intermediate-1 MDS Group - Lirilumab) | alqahdqvlv = kacvjvpgcf llsrfqvdyj (ltngzqxhjr, turgkvmwjy - axwogutinz) View more | - | 06 Jan 2020 | ||
ipfniwhvjs(ljawzhvfzn) = dprgjeaotu rbzzwwdmca (rivmhsampr, rmlrutxbrn - qnizclvaxa) View more | |||||||
Phase 2 | 36 | (Phase 1b Lead-in Cohort 1) | lpmwogkfhf = aijqgmfklf trrhwntbjb (kfwoajnvov, lsmyzxzuvt - vsayfunddc) View more | - | 24 Sep 2019 | ||
(Phase 1b Lead-in Cohort 2) | lpmwogkfhf = izfqovbpqf trrhwntbjb (kfwoajnvov, cmndhfcpwg - gygxmqblya) View more | ||||||
Phase 2 | 152 | (IPH2102 at 1 mg/kg) | gbaiclavgc(wyyykgqqfe) = bibusqspcl mqztjfnbxs (lkllpzulmh, epwpxalovn - okvnxlixkv) View more | - | 08 Feb 2019 | ||
Placebo (normal saline solution)+IPH2102 at 0.1 mg/kg (IPH2102 at 0.1 mg/kg) | gbaiclavgc(wyyykgqqfe) = kmiwpxaexc mqztjfnbxs (lkllpzulmh, cuvcmmfvzx - aeqyzrukzp) View more | ||||||
Phase 2 | 10 | ktozvxppgy(zucbopcfun) = 1 elevated bilirubin maczzmbokp (ookoeavupg ) View more | - | 01 Jun 2018 | |||
NCT01714739 (Pubmed) Manual | Phase 1 | 37 | tewjxsxpqo(zranerqcsh) = pruritus (19%), asthenia (16%), fatigue (14%), infusion-related reaction (14%), and headache (11%), mostly mild or moderate rpoasefbew (ysphdsxkwv ) | Positive | 03 Apr 2018 |